Drug Trial Radar · NCT06773364
Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,423
Planned (sponsor's estimate)
Start
Apr 30, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Shanghai East HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. EAST aims to evaluate the effects of pre-hospital levetiracetam and different head positions initiated in ambulance settings on the functional outcome of participants assessed at 90 days.
Conditions
- Suspected Stroke
Interventions
LevetiracetamDrug
Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH
Guide-recommended managementOther
To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.
The lying flat (0°) head positionOther
Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.
The sitting-up (≥30°) head positionOther
Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional shift (improvement) in 7-level mRS scoresTime frame: 90 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Si County People's Hospital
Suzhou, Anhui, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.